QIAGEN leverages QuantiFERON®-TB technology to advance global efforts against TB TB IGRA testing now accessible in high burden, low resource and decentralized settings Study data also showcased at the ...
QIAGEN’s New Generation of QuantiFERON TB Test Gains Chinese Approval and Renewed WHO Recommendation
HILDEN, Germany & GERMANTOWN, Md. & SHANGHAI--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its QuantiFERON tuberculosis (TB) testing solution has ...
QIAGEN QGEN recently reached a major landmark in the field of tuberculosis (TB) testing. On World TB Day, the company announced that since the lime of its launch, the company’s QuantiFERON blood test ...
CE-marked workflow enables efficient, high-throughput screening for tuberculosis control efforts in Europe and other markets; introduction in United States expected in 2019 and China in 2020 QIAGEN ...
GERMANTOWN, Md. & HILDEN, Germany & SALUGGIA, Italy--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and DiaSorin (FTSE MIB: DIA) today announced the expansion of their QuantiFERON ...
Data on performance of QuantiFERON-TB Gold In-Tube test (QFT) and tuberculin skin test (TST) in children with active tuberculosis from high burden countries in the context of micronutrient deficiency ...
Please provide your email address to receive an email when new articles are posted on . ATLANTA — Repeat, routine testing for latent tuberculosis infection among patients receiving biologics is both ...
Dutch firm wants to incorporate QuantiFERON technology into QIAsymphony and QIAensemble platforms. The board of Australian diagnostics firm Cellestis is backing a proposed $355 million, A$3.55 (about ...
Background: Diagnosis and treatment of latent tuberculosis infection (LTBI) is the most effective strategy to control tuberculosis (TB) among patients with HIV infection. The tuberculin skin test (TST ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback